Clinical outcomes of patients with endometrioid epithelial ovarian cancer following surgical treatment Journal Article
| Authors: | Cybulska, P.; Tseng, J.; Zhou, Q. C.; Iasonos, A.; Delair, D. F.; Mueller, J. J.; Long Roche, K. C.; Abu-Rustum, N. R.; Leitao, M. M. Jr |
| Article Title: | Clinical outcomes of patients with endometrioid epithelial ovarian cancer following surgical treatment |
| Abstract: | Background: Endometrioid epithelial ovarian cancer (EEOC) is rare, and its management poorly defined. We examined factors associated with 5-year progression-free survival (PFS) after surgery for EEOC. Methods: Retrospective study: treatment and outcomes of all EEOC patients undergoing initial surgery at, or presenting to, our institution within 3 months of initial surgery, 1/2002-9/2017. Results: In total, 212 patients were identified. Median follow-up, 63.9 months (range, 0.7–192); median age at diagnosis, 52 years (range, 20–88); disease stage: I, n = 145 (68%); II, n = 47 (22%); III/IV, n = 20 (9%); FIGO grade: 1, 127 (60%); 2, 66 (31%); 3, 17 (8%); unknown, 2 (1%). One hundred twenty-eight (60%) had endometriosis; 75 (35%), synchronous endometrioid endometrial cancer (80%, IA); 101 (48%), complete surgical staging; 8 (5%), positive pelvic lymph nodes (LNs); 6 (4%), positive para-aortic LNs; 176 (97%), complete gross resection; 123 (60%), postoperative chemotherapy; 56(28%), no additional treatment. Five-year PFS, 83% (95% confidence interval [CI]: 76.6%–87.8%); 5-year overall survival (OS), 92.7% (95% CI: 87.7%–95.8%). Age, stage, and surgical staging were associated with improved 5-year PFS, and younger age at diagnosis with improved 5-year OS (p < 0.001). Chemotherapy did not improve 5-year PFS in IA/IB versus observation, but improved survival in IC (hazard ratio [HR]: 1.01, 95% CI: 0.22–4.59, p = 0.99; HR: 0.17, 95% CI: 0.04–0.7, p = 0.006). Conclusions: Age, stage, and full surgical staging were associated with improved 5-year PFS. Chemotherapy showed no benefit in IA/IB disease. © 2021 Wiley Periodicals LLC |
| Keywords: | chemotherapy; lymph node metastasis; progression-free survival; endometrioid epithelial ovarian cancer |
| Journal Title: | Journal of Surgical Oncology |
| Volume: | 124 |
| Issue: | 5 |
| ISSN: | 0022-4790 |
| Publisher: | Wiley Blackwell |
| Date Published: | 2021-10-01 |
| Start Page: | 846 |
| End Page: | 851 |
| Language: | English |
| DOI: | 10.1002/jso.26597 |
| PUBMED: | 34270102 |
| PROVIDER: | scopus |
| PMCID: | PMC8429081 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 1 October 2021 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
-
575Leitao -
888Abu-Rustum -
254Zhou -
363Iasonos -
247Long Roche -
106DeLair -
186Mueller -
27Tseng -
17Cybulska
Related MSK Work